Skip to content

Use of Mellitor Sensor for Continuous Glucose Monitoring - An Ex-Vivo Study

Use of Mellitor Sensor for Continuous Glucose Monitoring - An Ex-Vivo Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00746642
Enrollment
20
Registered
2008-09-04
Start date
2009-10-31
Completion date
2010-10-31
Last updated
2009-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

glucose measurements

Brief summary

Most patients with diabetes mellitus have to measure their blood glucose levels quite often, in order to maintain a proper glycemic control. Current methods of self-monitoring of blood glucose are invasive, painful, uncomfortable, and only allow occasional, from time-to-time, measurements. Real-time continuous monitoring would provide a helpful tool for improvement of glycemic control, thus decreasing the incidence of hypoglycemia and improving glucose control. The Mellitor sensor is a new concept of continue glucose monitoring device. The Mellitor device is an implantable continuous glucose monitoring sensor that is intended for detection episodes of hyperglycemia and hypoglycemia in diabetic patients, and facilitates both acute and long-term therapy adjustments. This study was design in order to evaluate glucose measurement capabilities by the Mellitor sensor that is being developed. Transudate liquid samples, withdrawn in a clinical procedure and normally immediately disposed, will be used for glucose measurement by the Mellitor sensor. Study Design This study is an ex-vivo comparative study. 20 patients will be recruited for the study, according to patients' inflow and meeting eligibility criteria. Study Goal Study objective is to evaluate the feasibility of the Mellitor Sensor technology for glucose level measurement. Study Endpoint Mellitor technology feasibility will be established by comparing Mellitor glucose measurements results, based on transudate/exudates liquid withdrawal for other medical reasons, to gold standard, Yellow Springs glucose analyzer, or a comparable, calibrated and approved device using the same transudate/exudates liquid. Interdevice variability should be within 10%.

Interventions

DEVICEMellitor device for glucose measurement

Glucose measurement using Mellitor device

Sponsors

Mellitor
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male/Female aged 18 and up. * Subject was scheduled for transudate/exudate liquid withdrawal. * Subject able to comprehend and give informed consent for participation in this study. * Signed Informed Consent Form

Exclusion criteria

* Known cognitive or psychiatric disorder. * Subjects with HIV. * Subject refuses to sign inform consent form.

Design outcomes

Primary

MeasureTime frame
Mellitor technology feasibility will be established by comparing Mellitor glucose measurements results to gold standard, Yellow Springs glucose analyzer, or a comparable. Interdevice variability should be within 10%.during glucose measurements

Countries

Israel

Contacts

Primary ContactHanna Levy, Dr.
hanna@qsitemed.com(972)-4-638-8837

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026